IN2014DN09963A - - Google Patents

Download PDF

Info

Publication number
IN2014DN09963A
IN2014DN09963A IN9963DEN2014A IN2014DN09963A IN 2014DN09963 A IN2014DN09963 A IN 2014DN09963A IN 9963DEN2014 A IN9963DEN2014 A IN 9963DEN2014A IN 2014DN09963 A IN2014DN09963 A IN 2014DN09963A
Authority
IN
India
Prior art keywords
cancer
treatment
relates
soluble peptide
krfyvvmwkk
Prior art date
Application number
Inventor
Santos Susin
Pierre Launay
Philippe Karoyan
Hélène Merle-Beral
Original Assignee
Inst Nat Sante Rech Med
Université Pierre Et Marie Curie Upmc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Université Pierre Et Marie Curie Upmc filed Critical Inst Nat Sante Rech Med
Publication of IN2014DN09963A publication Critical patent/IN2014DN09963A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO: 1) or a function- conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.
IN9963DEN2014 2012-06-06 2013-06-06 IN2014DN09963A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305636 2012-06-06
PCT/EP2013/061727 WO2013182650A1 (en) 2012-06-06 2013-06-06 Method and pharmaceutical composition for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
IN2014DN09963A true IN2014DN09963A (en) 2015-08-14

Family

ID=48669879

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9963DEN2014 IN2014DN09963A (en) 2012-06-06 2013-06-06

Country Status (8)

Country Link
US (4) US9198949B2 (en)
EP (2) EP2858660B1 (en)
JP (2) JP2015520178A (en)
CN (1) CN104519898A (en)
DK (1) DK3434276T3 (en)
ES (1) ES3009438T3 (en)
IN (1) IN2014DN09963A (en)
WO (1) WO2013182650A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014160183A1 (en) * 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
EP3454879B1 (en) * 2016-05-10 2021-12-22 INSERM (Institut National de la Santé et de la Recherche Médicale) New compounds and pharmaceutical use thereof in the treatment of cancer
EP3243522A1 (en) * 2016-05-10 2017-11-15 Université Pierre et Marie Curie (Paris 6) Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death
JP7537074B2 (en) * 2016-05-10 2024-08-21 ソルボンヌ ウニベルシテ Agents that activate CD47 and their use in treating inflammation - Patents.com
CN107703109B (en) * 2016-08-08 2021-01-15 华东理工大学 Two-dimensional molybdenum sulfide polypeptide composite material and application thereof in targeting CD47 cancer marker
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP3650036A1 (en) 2018-11-06 2020-05-13 Sorbonne Universite Synthetic peptides inducing immunogenic cell death
US20220160812A1 (en) * 2019-05-22 2022-05-26 Cytopharma Gmbh A pharmaceutically active substance
CN116726188A (en) * 2022-11-29 2023-09-12 浙江大学杭州国际科创中心 A kind of nanopyroptosis drug targeting CD47 protein and its preparation and application
CN116831988A (en) * 2023-06-13 2023-10-03 南京鼓楼医院 A liposome ophthalmic preparation loaded with peptide mimetic PKHB1 and its preparation method

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
JPH0853494A (en) * 1994-06-07 1996-02-27 Nihon Medi Physics Co Ltd Tumor affinity peptide, radiodiagnostic agent and radiotherapeutic agent containing the peptide
AU684348B2 (en) 1994-06-07 1997-12-11 Nihon Medi-Physics Co., Ltd. Tumor affinity peptide, and radioactive diagnostic agent and adioactive therapeutic agent containing the peptide
US5610271A (en) * 1995-06-07 1997-03-11 Torrey Pines Institute For Molecular Studies Kappa receptor selective opioid peptides
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
ES2258798T3 (en) * 1996-11-27 2006-09-01 Boston Heart Foundation, Inc. NEW PROTEINS OF UNION TO HYPOPROTEINS OF LOW DENSITY AND ITS USE FOR THE DIAGNOSIS AND TREATMENT OF ARTEROSCLEROSIS.
US6579520B2 (en) 1998-05-15 2003-06-17 Genentech, Inc. IL-17 related mammalian cytokine polypeptides (IL-17E)
US6569645B2 (en) 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP1283850A2 (en) 2000-05-26 2003-02-19 Beth Israel Deaconess Medical Center Thrombospondin type 1 repeat polypeptides
US20060188508A1 (en) * 2005-02-17 2006-08-24 Cohen Stanley N Methods and compositions for modulating angiogenesis
JP2009013142A (en) * 2007-07-09 2009-01-22 Kyoto Univ Sustained release mesoporous silica
JP5661988B2 (en) * 2008-02-26 2015-01-28 株式会社ペプタイドドア Muscarinic receptor activators and peptides

Also Published As

Publication number Publication date
DK3434276T3 (en) 2025-01-20
US9198949B2 (en) 2015-12-01
US20150126456A1 (en) 2015-05-07
US20160039908A1 (en) 2016-02-11
ES3009438T3 (en) 2025-03-26
EP2858660A1 (en) 2015-04-15
WO2013182650A1 (en) 2013-12-12
JP2018057394A (en) 2018-04-12
US20190135898A1 (en) 2019-05-09
US20170362302A1 (en) 2017-12-21
EP3434276B1 (en) 2024-10-30
EP2858660B1 (en) 2018-09-05
CN104519898A (en) 2015-04-15
US10759843B2 (en) 2020-09-01
EP3434276A1 (en) 2019-01-30
JP2015520178A (en) 2015-07-16

Similar Documents

Publication Publication Date Title
IN2014DN09963A (en)
MX360208B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX363136B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX360211B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX340014B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX2012008998A (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX2012009000A (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX340016B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
NZ601818A (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers
EA033399B1 (en) Glucagon analogues with increased solubility and/or stability and use thereof
WO2017009843A3 (en) Compositions, articles of manufacture and methods for treating cancer
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
WO2016004906A3 (en) Tumor vascular disrupting agent polypeptide, gene, expression vector, and use thereof
NZ708990A (en) Method for activating helper t cell
SG10201407944TA (en) Imp-3 oligopeptides and vaccines including the same
RU2015112625A (en) Peptide, peptide use for the treatment of cardiovascular diseases, nucleotide sequence, expression vector, host cell, pharmaceutical composition
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
IN2014DN06920A (en)
EA033437B9 (en) Fc GAMMA RECEPTOR IIB AND USE THEREOF FOR TREATING OR PREVENTING INFLAMMATORY AND/OR AUTOIMMUNE DISEASES
NZ609474A (en) Fviii peptides for immune tolerance induction and immunodiagnostics
NZ603442A (en) Treatment of proliferative diseases
EP3925968A3 (en) Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
NZ709120A (en) Beta-hexosyl-transferases and uses thereof
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same